| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 16.829 | 15.075 | 16.768 | 18.704 | 18.094 | 20.459 | 19.324 | 16.942 | 381.002 | 628.684 |
| Total Income - EUR | 16.829 | 15.075 | 16.768 | 18.753 | 18.094 | 20.472 | 19.470 | 29.890 | 387.089 | 636.161 |
| Total Expenses - EUR | 16.288 | 14.666 | 15.462 | 17.290 | 17.356 | 19.223 | 18.218 | 24.111 | 380.097 | 607.567 |
| Gross Profit/Loss - EUR | 541 | 410 | 1.305 | 1.463 | 738 | 1.250 | 1.253 | 5.779 | 6.993 | 28.593 |
| Net Profit/Loss - EUR | 36 | -43 | 802 | 901 | 195 | 679 | 668 | 5.001 | 3.375 | 24.059 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 4 |
Check the financial reports for the company - Ascom Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 64.627 | 57.031 | 41.875 |
| Current Assets | 1.757 | 1.610 | 1.636 | 2.379 | 3.032 | 3.672 | 3.475 | 22.965 | 93.055 | 149.455 |
| Inventories | 1.214 | 1.207 | 1.344 | 1.982 | 2.654 | 3.348 | 3.085 | 21.138 | 52.241 | 75.514 |
| Receivables | 417 | 291 | 180 | 167 | 240 | 221 | 162 | 0 | 37.842 | 65.505 |
| Cash | 126 | 112 | 113 | 230 | 139 | 103 | 227 | 1.827 | 2.972 | 8.437 |
| Shareholders Funds | -14.669 | -14.562 | -13.557 | -12.408 | -11.930 | -11.025 | -10.112 | -5.143 | -1.752 | 22.316 |
| Social Capital | 45 | 45 | 0 | 0 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 16.426 | 16.172 | 15.194 | 14.787 | 14.963 | 14.697 | 13.587 | 92.735 | 151.838 | 169.015 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Ascom Pharma Srl